Protein Kinase B Inhibitors Market

Protein Kinase B Inhibitors Market Overview

Protein kinase B are enzymes that play crucial role in managing cell process like cell survival, tumour formation, angiogenesis, apoptosis, glucose metabolism, cell migration and transcription.

Protein kinase B, also known as Akt, is found in three forms namely, Akt1, Akt2 and Akt3. While Akt1 is responsible for cell survival pathways, Akt2 facilitates insulin signalling pathways, the role of Akt3 is not very clear. Protein kinase B inhibitors are molecules used to deactivate protein kinase B enzymes.

COVID-19 has been found to be severely affecting people with co-morbidities. It has been argued that individuals battling cancer might be at a higher risk of mortality if infected from COVID-19.

Protein Kinase B Inhibitors Market: Drivers and Restraints

Increasing prevalence of the various types forms of cancer worldwide is a major driver for the growth of the protein kinase B inhibitors market. Cancer related complications is the second leading cause of mortality after cardiovascular diseases in the world which in turn would be pushing the global protein kinase B inhibitors market.

Rising awareness among the people increased initiatives by the various governments worldwide along with discovery of promising pipeline of therapies and drugs and ever increasing collaborations among various cancer research institutes be bound to drive the global protein kinase B inhibitors market.

Protein kinases are considered to be the most crucial categories of targets for oncology research and drug discovery due to their significant role in cell survival hence it is quite certain that pharmaceutical industry will be keen to study them further. This would consequently drive the global protein kinase B inhibitors market. Major barriers to the global protein kinase B inhibitors market are high cost involved in the treatment of cancer.

Long challenging phases of trials followed by stringent regulatory regimes can hamper the growth of global protein kinase B inhibitors market. Further serious side effects from various therapies can pull the global protein kinase B inhibitors market backwards. Financial constraints and inadequate cancer-care infrastructure in developing countries can be limiting factors for protein kinase B inhibitors market.

Protein Kinase B Inhibitors Market: Overview

The market for protein kinase B inhibitors can be expected to register robust growth as by the end of 2025 the world is expected to have 5 million people affected by one or the other form of cancer. Based on product type Akt1 segment can be estimated to see robust growth in the global protein kinase B inhibitors market.

Based on indication type breast cancer segment is poised to register steady growth in the global protein kinase B inhibitors market owing to the maximum prevalence of breast cancer among all types of cancer. By distribution channel type the hospital pharmacies are expected to be the most lucrative in the global protein kinase B inhibitors market.

Protein Kinase B Inhibitors Market: Region-wise Outlook

Australia and New Zealand from Oceania have recorded maximum prevalence of cancer. Accordingly it can be expected that Oceania would be driving the global protein kinase B inhibitors market.

Europe especially Western Europe can be witnessed to occupy the second largest chunk in the global protein kinase B inhibitors market owing to the high prevalence of cancer in the countries like Ireland Hungary France. Considering high incidence rates other markets like North America South Asia East Asia and Latin America can be estimated to be equally attractive for the global protein kinase B inhibitors market.

Protein Kinase B Inhibitors Market: Key Players

Key players active the global protein kinase B inhibitors market are

• Eli Lilly
• Glaxosmithkline
• Pfizer
• Johnson & Johnson
• AstraZeneca
• Novartis
• Roche
• Celgene
• Sierra Oncology
• AbbVie
• Vernalis Research

The research report presents a comprehensive assessment of the market and contains thoughtful insights facts historical data and statistically supported and industry-validated market data. It also contains projections using a suitable set of assumptions and methodologies.

The research report provides analysis and information according to market segments such as geographies application and industry.

The report covers exhaust analysis on

• Market Segments
• Market Dynamics
• Market Size
• Supply & Demand
• Current Trends/Issues/Challenges
• Competition & Companies involved
• Indication
• Value Chain

Regional analysis includes

• North America (U.S. Canada)
• Latin America (Mexico. Brazil)
• Europe (Germany U.K France Italy Spain)
• South Asia (India ASEAN Countries)
• East Asia (Japan China & South Korea)
• Oceania (Australia & New Zealand)
• Middle East and Africa (GCC Countries South Africa Northern Africa)

The report is a compilation of first-hand information qualitative and quantitative assessment by industry analysts inputs from industry experts and industry participants across the value chain.

The report provides in-depth analysis of parent market trends macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.

Protein Kinase B Inhibitors Market: Segmentation

The global protein kinase B inhibitors market is segmented based on the product type, indication type, end user, distribution channel and region.

Product Type

• Akt1
• Akt2
• Akt3

Indication Type

• Thyroid Cancer
• Breast Cancer
• Melanoma
• Non-Small Cell Lung Cancer
• Others

End user

• Hospitals
• Speciality Research Institutes
• Academic Research Institutes
• Others

Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Drug Stores
• Online Pharmacies